RxDoctor Payments Data

Travis Miller, DO

Sports Medicine · Fleetwood, PANPI 1013322809

Payments from drug & device makers

$259in general payments, 2019–2025

Across 12 payments — averaging $21.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$92
  • Lilly USA, LLC$41
  • AstraZeneca$34
  • Boehringer Ingelheim$27
  • Novartis$26
  • Exact Sciences$22
  • plus $18 from 1 others

What the payments were for

  • Food & beverage$259100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk4$92
Lilly USA, LLC2$41
AstraZeneca2$34
Boehringer Ingelheim1$27
Novartis1$26
Exact Sciences1$22
Tenex Health Inc.1$18

How this compares

$259 in reported general payments places this provider in the 35th percentile of 311 sports medicine providers in Pennsylvania.

See all sports medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$95,568
Medicare patients
337
Services billed
1,710

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide70$84,323
EliquisApixaban60$55,080
JardianceEmpagliflozin27$30,794
OzempicSemaglutide18$25,973
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$19,141
JanuviaSitagliptin Phosphate11$17,842
XareltoRivaroxaban11$16,319
FarxigaDapagliflozin Propanediol14$12,860
MyrbetriqMirabegron17$11,857
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$11,202
Tresiba Flextouch U-100Insulin Degludec19$8,923
EntrestoSacubitril/Valsartan11$7,730
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$6,190
Atorvastatin Calcium574$6,073
Breo ElliptaFluticasone/Vilanterol14$6,055

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$41$84,32370 claims
Boehringer IngelheimJardiance$27$30,79427 claims
Novo NordiskOzempic$92$25,97318 claims
AstraZenecaFarxiga$34$12,86014 claims
NovartisEntresto$26$7,73011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 311 sports medicine providers in Pennsylvania.

Other sports medicine in Fleetwood

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →